Cingulate Inc. (CING)
- Previous Close
0.7661 - Open
0.7610 - Bid 0.7445 x 100
- Ask 0.8306 x 100
- Day's Range
0.7610 - 0.8300 - 52 Week Range
0.7000 - 21.8000 - Volume
90,195 - Avg. Volume
175,163 - Market Cap (intraday)
4.782M - Beta (5Y Monthly) -0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-26.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.00
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
www.cingulate.comRecent News: CING
Performance Overview: CING
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CING
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CING
Valuation Measures
Market Cap
4.78M
Enterprise Value
4.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.49
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-190.98%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.53M
Diluted EPS (ttm)
-26.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
52.42k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.36M
Research Analysis: CING
Company Insights: CING
CING does not have Company Insights